AAVantgarde is a clinical stage, Italian headquartered, international biotechnology company. It is validating its two proprietary AAV platforms in the clinic in two inherited retinal diseases with the potential that its technology could extend into many disease areas. AAV gene therapy has been limited by transgene capacity, and the Company’s platforms enable delivery of large genes to tissue and cells in vivo.
Location: Italy, Lombardy, Milan
Employees: 1-10
Founded date: 2020
Investors 2
| Date | Name | Website |
| 18.06.2023 | Forbion | forbion.co... |
| 15.06.2023 | Atlas Vent... | atlasventu... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large anim... | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotec... | forbion.co... |
| 06.06.2023 | AAVantgarde Bio Closes €61M Series A Financing | AAVantagarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing two propriet... | finsmes.co... |
| - | AAVantgarde Bio | “Homepage - AAVantgarde Bio” | fastfounde... |